United Therapeutics (UTHR) announced the first clinical xenotransplantation in its EXPAND study of the UKidney in patients with end-stage renal disease. The successful transplant operation was performed at NYU Langone Health.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $587 from $569 at RBC Capital
- United Therapeutics price target raised to $525 from $500 at H.C. Wainwright
- United Therapeutics price target raised to $447 from $435 at Morgan Stanley
- United Therapeutics: Hold Rating Amid Optimistic Partnership Prospects and Adjusted Revenue Goals
- United Therapeutics Reports Record Q3 2025 Results